Association of miR-372 and miR-137 Expression with Metastasis in Patients with Lung Cancer
Archives of Advances in Biosciences,
Vol. 11 No. 1 (2020),
8 January 2020
,
Page 50-60
https://doi.org/10.22037/aab.v11i1.27752
Abstract
Introduction: Identification of metastatic miRNAs and understanding their complex functions provides prognostic and diagnostic bio markers In this study, the expression of miR-372, fgf-9 gene, miR-137 and cdc42 gene was evaluated in the serum of patients with lung cancer.
Materials and Methods: In the present study, 50 serum samples were collected from healthy individuals and 50 serum samples from people with NSCLC from Masih Daneshvari Hospital in Tehran. Clinicopathological information was collected through questionnaires.
In the molecular study, changes in expression of miR-372, miR-137, fgf-9 and cdc42 genes in healthy individuals and those with lung cancer were evaluated using Real Time PCR.
Results: Expression of miR-372, fgf-9 and cdc42 genes in the first to third stage serum of metastases and expression of miR-137 in serum of the first and second stages of the disease were not significantly different from the normal one. However, in the serum of the fourth stage of the disease, expression of miR-372 and cdc42 gene were significantly increased by 7.3 and 3.4 folds than normal subjects, while in the serum of the fourth stage of the disease, the expression of fgf-9 gene was significantly reduced by 4.46 fold .The expression of miR-137 in the serum of the third and fourth stages of the disease was significantly reduced by 3.2 and 6.8 fold compared to the normal serum
Conclusion: It is likely that the expression of miR-372, miR-137, fgf-9 and cdc42 genes in human serum could be used to predict the stage of lung cancer metastasis.
- lung cancer
- miR-372
- fgf-9 gene
- miR-137
- cdc42 gene
How to Cite
References
Cooper WA., Lam DCL, O’Toole, SA and Minna, JD. Molecular biology of lung cancer. J Thorac Dis 2013 Oct; 5: S479-S490.
Hassanipour S, Mokhtari A.M, Fathalipour M and Salehiniya H. THE INCIDENCE OF LUNG CANCER IN IRAN: A SYSTEMATIC REVIEW AND META-ANALYSIS. World Cancer Research Journal 2017 Dec 20; 4(4): 1-7.
Molavi Vardanjani H, Zeinali, M, Radmerikhi, S and Hadipour M. Lung Cancer Prevalence in Iran by Histologic Subtypes. Adv Biomed Res 2017 Aug 31; 6(111): 1-5.
Zappa C, Mousa, SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 2016 Jun ; 5 (3): 288-300.
Guz M, Rivero-Müller A, Okon E, Stenzel-Bembenek A, Polberg K, Slomka, M, et al. MicroRNAs-Role in Lung Cancer. Disease Markers 2014 Mar13; 2014: 1-13.
Li M, Li J, Ding X, He M and Cheng, SY. microRNA and cancer. The AAPS journal 2010 Sep; 12 (3): 309-317.
Wu G, Wang Y, Lu X, He H, Liu H, Meng X, et al. Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma. BMC Cancer 2015 March; 159182):( 1-12.
Zhu X, Li Y, Shen H, Li H, Long L, Hui L, et al. miR‐137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS letter 2013 Jan 4; 587(1): 73-81.
Ohgino K, Soejima K, Yasuda H, Hayashi Y, Hamamoto J, Naoki K, et al. Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. Lung Cancer 2014 jan; 83 (1): 90-96.
Wu XI, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, et al. Multiple Synostoses Syndrome Is Due to a Missense Mutation in Exon 2 of FGF9 Gene. The American Journal of Human Genetics 2009 Jul10; 85 (1): 53–63.
Chen OY, Jiao DM, Yao QH, Yan J, Song J, Chen FY, et al. Expression analysis of Cdc42 in lung cancer and modulation of its expression by curcumin in lung cancer cell lines. International Journal Of Oncology 2012 January; 40 (5): 1561-1568.
Powell JE, Fung J, Shakhbazov K, Sapkota, Y, Cloonan N, Hemani G, et al. Endometriosis risk alleles at 1p36.12 act through inverse regulation of CDC42 and LINC00339., Human Molecular Genetics 2016 September; 25 (22): 5046–5058.
Wang Q, Liu S, Zhao X, Wang Y, Tian D and Jiang W. MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous cell carcinoma. Cancer Medicine 2017 Jun; 6 (6): 1323-30.
Mahmoudi E, Cairns MJ. MiR-137: an important player in neural development and neoplastic transformation. Molecular Psychiatry 2017 Jun; 22(1): 44–55.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144 (5): 646-74.
Liu X, Chen L, Tian, XD and Zhang T. MiR-137 and its target TGFA modulate cell growth and tumorigenesis of non-small cell lung cancer. Eur Rev Med Pharmacol Sci 2017 Feb; 21 (3): 511-517.
Guan X, Zong ZH, Chen S, Sang XB, Wu DD, Wang LL, et al. The role of miR-372 in ovarian carcinoma cell proliferation. Gene 2017 Aug15; 624: 14-20.
Chen R, Zhang Z, Zhang C, Wu H and Yang S. miR-137 inhibits the proliferation of human non-small cell lung cancer cells by targeting SRC3. ONCOLOGY LETTERS 2017 May; 13 (5): 3905-3911.
Kim JO, Gazala S, Razzak R, Guo L, Ghosh S, Roa WH, et al. Non-small Cell Lung Cancer Detection Using MicroRNA Expression Profiling of Bronchoalveolar Lavage Fluid and Sputum. Anticancer Research 2015 Apr; 35 (4): 1873-80.
Lee JM, Cho KW, Kim EJ, Tang Q, Kim KS, Tickle C, et al. A contrasting function for miR-137 in embryonic mammogenesis and adult breast carcinogenesis. Oncotarget 2015 Sep8; 6 (26): 22048-59.
Yeh LY, Liu CJ, Wong YK, Chang C, Lin SC, Chang KW. miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo. Oncotarget 2015 Mar20; 6 (8): 6062-75.
Mallick R, Joshi S, D Kannisto E, K Patnaik S and Yendamuri, S. MicroRNA miR-372 Enhances the Malignant Potential of Lung Cancer Cells. Journal of the American College of Surgeons 2015 October; 221 (4S1): S151.
Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA Signature Predicts Survival and Relapse in Lung Cancer. Cancer Cell 2008February;13(1):48-57.
- Abstract Viewed: 348 times
- PDF Downloaded: 185 times